---

Revisiting novel interventions in melanoma

Full Text PDF

---

Review Article

Author Details : Sunil Chaudhry*

Volume : 8, Issue : 2, Year : 2023

Article Page : 98-103

https://doi.org/10.18231/j.ijcaap.2023.017

Suggest article by email

Get Permission

Abstract

Malignant tumor which that arises from uncontrolled proliferation of melanocytes is melanoma. Its rare tumor in India, compared to other tropical countries. Fair skin populations have higher incidences of melanoma. The relative mortality is reduced to nearly half with scrupulous use of sunscreens - SPF 50 blocks 98% of UVB rays. Melanomas are observed more in countries like Australia and New Zealand (due to actinic rays (UV B rays) of light) and thus guidelines from their ministry of health has been published. First line drugs for melanoma unresectable stage III or IV metastatic disease include Pembrolizumab and Nivolumab. Studies have shown that Pembrolizumab improved overall survival (OS) compared with ipilimumab. Ipilimumab/Nivolumab combination was significantly better than ipilimumab monotherapy. Similarly nivolumab/ipilimumab combination therapy was better than compared with ipilimumab monotherapy regardless of BRAF mutation status. Vemurafenib and Dabrafenib (Tyrosine kinase inhibitors) were developed to inhibit BRAF with mutations at V600. Dabrafenib/Trametinib or Vemurafenib/Cobimetinib combinations were better than monotherapy. Surgery remains the best option for cure in localized, invasive melanoma, with good overall survival rate.
 

Keywords: Metastatic melanoma, Immunotherapy, Targeted therapy BRAFV600, chemotherapy, Radiotherapy, Surgery

How to cite : Chaudhry S, Revisiting novel interventions in melanoma. IP Int J Compr Adv Pharmacol 2023;8(2):98-103

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.